



Repurposing Research to Create Patient Impact in Blood Cancers

Description / Background

This Request for Proposals is seeking proposals to identify repurposed treatments for cancers originating in the blood or bone marrow, with preference given to proposals in multiple myeloma, myelodysplastic syndrome and myeloproliferative neoplasms. Repurposing research proposals in other types of blood cancers may also be considered.

We are interested in proprietary or generic drugs, devices, nutraceuticals or diagnostics that could be repurposed to develop "new" treatments for blood cancers, thereby improving patient outcomes and quality of life.

Repurposed therapies can be used alone or in combination with other therapies. Therapies must already have FDA approval or other availability for human use.

Our strongest interest is in projects that are ready for a proof of concept clinical trial supported by strong preclinical scientific evidence or clinical observations. We are also open to late stage preclinical work that would directly lead to repurposing clinical trials, if there is a clinical team ready to commence the clinical trial if the final preclinical work delivers the necessary data.

Diseases/Conditions

[Multiple myeloma](#)
[Myelodysplastic syndrome](#)
[Myeloproliferative Disorder](#)
[Blood cancers](#)
[myeloproliferative neoplasms](#)

Treatments

[Any repurposed drug, device, nutraceutical or diagnostic](#)

Project Type

- Human Clinical Trial
- Animal Trial

Timeline

Project Must Start by: 12-31-2018

Project Must Finish by: 01-01-2022

Do you have a preference for where the research should take place?

This research can take place anywhere in the world where good clinical practices can be assured. This RFP is open to any accredited academic research institution, as well as biotechs, pharmaceutical and medical device companies.

Do you have a preference for where you would like to see patient impact?

Our main focus is on repurposing research in multiple myeloma, myelodysplastic syndrome and myeloproliferative neoplasms, although proposals for other types of blood cancers may be considered. We are hopeful that any discovery would be useful around the globe wherever the repurposed therapy is available. In geographic areas where the repurposed therapy is not available, we will work to make it available, if it can save blood cancer patient lives.

Restrictions

None.

Other Information for Researchers

While clinical trials are preferred, late preclinical studies will be considered. Any preclinical Letters of Intent (LOIs) would be strengthened by a supporting letter from a clinical collaborator willing to begin clinical trials once positive results are seen.

Cost effectiveness, speed and patient impact are key ranking criteria for a successful Letter of Intent (LOI). LOIs will undergo a scientific review, with a subset selected for Full Grant submissions.

While there is no maximum submitted project budget, Cures Within Reach will fund no more than \$75,000, including the research institutional matching funds. Cures Within Reach will provide no more than 80% of the total requested funding, and the research institution will match 20% of the total requested funding.

If an LOI is selected for Full Grant submission, the Principal Investigator will provide a budget breakdown of the total requested funding. Funding cannot be used for any indirect costs, and up to 10% of the funding can be used toward direct project administrative costs.

Cures Within Reach funding must be late or final funding for the project. Cures Within Reach funding cannot be the first funding raised for a project, unless the total requested funding covers the entire cost.

Funding Available

Minimum \$25,000

Maximum \$75,000

Funding Description

While there is no maximum submitted project budget, Cures Within Reach will fund no more than \$75,000, including the research institutional matching funds. Cures Within Reach will provide no more than 80% of the total requested funding, and the research institution will match 20% of the total requested funding. If an LOI is selected for Full Grant submission, the Principal Investigator will provide a budget breakdown of the total requested funding. Funding cannot be used for any indirect costs, and up to 10% of the funding can be used toward direct project administrative costs. Cures Within Reach funding must be late or final funding for the project. Cures Within Reach funding cannot be the first funding raised for a project, unless the total requested funding covers the entire cost.

Open to co-funding

Co-Funding Description

We will accept projects that already have funding from another source and require additional funding. Cures Within Reach funding must be late or final funding for the project. We are open to working with other funders who share our desire to find solutions for blood cancer patients and are interested in these near term repurposing opportunities.

Due Date for Project Proposal Summary Submissions

05-11-2018
